Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry|July 21, 2021
Synthesis and interaction of terminal unsaturated chemical probes with Mycobacterium tuberculosis CYP124A1Luz Díaz-Storani, Anaelle A Clary, Diego M Moreno, et al.Bioorganic & Medicinal Chemistry|June 1, 2012
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1Jonathan B Johnston, Arti A Singh, Anaelle A Clary, et al.Molecular Microbiology|June 16, 2010
Mycobacterium tuberculosis CYP125A1, a steroid C27 monooxygenase that detoxifies intracellularly generated cholest-4-en-3-oneHugues Ouellet, Shenheng Guan, Jonathan B Johnston, et al.Antimicrobial Agents and Chemotherapy|April 14, 2010
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infectionPatricia S Doyle, Chiung-Kuang Chen, Jonathan B Johnston, et al.Molecular Cell|August 24, 2019
The Gene-Silencing Protein MORC-1 Topologically Entraps DNA and Forms Multimeric Assemblies to Cause DNA CompactionHyeongJun Kim, Linda Yen, Somsakul P Wongpalee, et al.Journal of Medicinal Chemistry|November 14, 2014
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51Debora F Vieira, Jun Yong Choi, Claudia M Calvet, et al.Plos Neglected Tropical Diseases|March 14, 2015
Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylaseLaura-Isobel McCall, Amale El Aroussi, Jun Yong Choi, et al.Proceedings of the National Academy of Sciences of the United States of America|August 17, 2016
Mouse MORC3 is a GHKL ATPase that localizes to H3K4me3 marked chromatinSisi Li, Linda Yen, William A Pastor, et al.Plos Neglected Tropical Diseases|August 4, 2012
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51Shamila S Gunatilleke, Claudia M Calvet, Jonathan B Johnston, et al.Journal of Medicinal Chemistry|August 8, 2014
4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potencyClaudia M Calvet, Debora F Vieira, Jun Yong Choi, et al.Pageof 3